Sio Capital Management, LLC
Reported holdings as of Q2 2026, from 31 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| ANTERIS TECHNOLOGIES GLOBAL | AVR | $54.6M | 5,545,984 | +4.76pp | 7q | +3.0%+$1.6M | |
| CENCORA INC | COR | $49.1M | 173,588 | +3.58pp | 3q | +72.0%+$20.6M | |
| MAXIMUS INC | MMS | $38.5M | 715,267 | -0.70pp | 8q | -7.0%-$2.9M | |
| ALLOGENE THERAPEUTICS INC | ALLO | $27.7M | 13,323,431 | - | new | NEW | |
| GLOBUS MED INC | GMED | $23.8M | 301,816 | - | new | NEW | |
| GSK PLC | GSK | $22.9M | 436,700 | +0.73pp | 2q | +13.2%+$2.7M | |
| TYRA BIOSCIENCES INC | TYRA | $22.2M | 695,315 | +0.35pp | 10q | +14.8%+$2.9M | |
| WAYSTAR HLDG CORP | WAY | $19.0M | 925,834 | -2.53pp | 3q | -43.6%-$14.7M | |
| SELLAS LIFE SCIENCES GROUP I OPT | SLS | $18.2M | options only | - | new | OPTIONS | |
| IDEAYA BIOSCIENCES INC | IDYA | $17.9M | 480,383 | - | new | NEW | |
| ORUKA THERAPEUTICS INC | ORKA | $16.9M | 177,118 | +1.86pp | 3q | +33.7%+$4.2M | |
| THE CIGNA GROUP | CI | $15.9M | 57,750 | - | new | NEW | |
| SANOFI SA | SNY | $15.5M | 364,200 | +0.92pp | 5q | +52.0%+$5.3M | |
| ICON PUB LTD CO | ICLR | $15.3M | 88,186 | -2.33pp | 3q | -71.2%-$37.9M | |
| VIATRIS INC | VTRS | $15.2M | 954,299 | - | new | NEW | |
| CROSS CTRY HEALTHCARE INC | CCRN | $14.5M | 1,098,393 | +0.92pp | 3q | HELD | |
| RAPPORT THERAPEUTICS INC | RAPP | $12.8M | 307,657 | +0.48pp | 4q | -16.1%-$2.5M | |
| ABBOTT LABORATORIES | ABT | $11.7M | 128,656 | -0.82pp | 2q | -31.0%-$5.3M | |
| CELCUITY INC | CELC | $11.5M | 110,022 | -1.27pp | 4q | -43.2%-$8.8M | |
| ZIMMER BIOMET HOLDINGS INC | ZBH | $11.3M | 131,445 | +1.06pp | 3q | +109.9%+$5.9M | |
| REGENERON PHARMACEUTICALS | REGN | $11.2M | 18,000 | - | new | NEW | |
| BRISTOL-MYERS SQUIBB CO | BMY | $11.1M | 193,500 | - | new | NEW | |
| MEDTRONIC PLC | MDT | $11.1M | 142,500 | - | new | NEW | |
| VIR BIOTECHNOLOGY INC | VIR | $11.0M | 1,075,274 | -0.11pp | 7q | -28.2%-$4.3M | |
| SENSEONICS HLDGS INC | SENS | $9.0M | 1,592,692 | +1.39pp | 3q | +1275.6%+$8.4M | |
| EYEPOINT INC | EYPT | $8.9M | 623,130 | +0.14pp | 2q | -13.7%-$1.4M | |
| CYBIN INC | HELP | $8.6M | 1,300,000 | - | new | NEW | |
| ANI PHARMACEUTICALS INC | ANIP | $8.1M | 97,305 | -1.60pp | 7q | -63.4%-$13.9M | |
| PROTARA THERAPEUTICS INC | TARA | $7.3M | 1,921,872 | -0.26pp | 3q | -2.4%-$183.2K | |
| RELMADA THERAPEUTICS INC | RLMD | $6.9M | 1,003,562 | +0.19pp | 2q | +4.0%+$266.8K | |
| TANGO THERAPEUTICS INC | TNGX | $6.5M | 208,500 | - | new | NEW | |
| AQUESTIVE THERAPEUTICS INC | AQST | $6.2M | 1,486,175 | -0.12pp | 6q | -22.7%-$1.8M | |
| DIANTHUS THERAPEUTICS INC | DNTH | $5.8M | 59,254 | -3.50pp | 6q | -84.0%-$30.3M | |
| SIONNA THERAPEUTICS INC | SION | $5.6M | 127,808 | -0.76pp | 2q | -56.6%-$7.3M | |
| OCULAR THERAPEUTIX INC | OCUL | $5.3M | 539,493 | -0.30pp | 2q | -44.3%-$4.2M | |
| ZENAS BIOPHARMA INC | ZBIO | $5.3M | 208,557 | -0.05pp | 2q | -37.1%-$3.1M | |
| BRIGHT MINDS BIOSCIENCES INC | DRUG | $5.2M | 73,952 | -0.04pp | 7q | -14.1%-$851.6K | |
| ONKURE THERAPEUTICS INC | OKUR | $4.9M | 1,078,965 | +0.17pp | 2q | HELD | |
| SAVARA INC | SVRA | $3.8M | 617,675 | +0.15pp | 7q | +0.6%+$23.3K | |
| PMV PHARMACEUTICALS INC | PMVP | $3.5M | 2,634,137 | +0.04pp | 9q | -14.4%-$592.9K | |
| AVEANNA HEALTHCARE HLDGS INC | AVAH | $3.2M | 369,036 | - | new | NEW | |
| OVID THERAPEUTICS INC | OVID | $2.7M | 1,005,334 | +0.05pp | 7q | -19.7%-$664.6K | |
| IMMUNOME INC | IMNM | $2.6M | 124,168 | -0.08pp | 2q | -24.8%-$867.6K | |
| HIMS & HERS HEALTH INC OPT | HIMS | $2.6M | options only | - | new | OPTIONS | |
| AN2 THERAPEUTICS INC | ANTX | $2.6M | 529,933 | +0.10pp | 2q | -19.4%-$616.0K | |
| SERINA THERAPEUTICS INC | SER | $1.9M | 1,000,000 | +0.04pp | 2q | HELD | |
| ALIGOS THERAPEUTICS INC | ALGS | $1.9M | 327,237 | -0.04pp | 6q | HELD | |
| IBIO INC | IBIO | $1.6M | 904,268 | +0.02pp | 3q | HELD | |
| XILIO THERAPEUTICS INC | XLO | $1.5M | 152,464 | +0.06pp | 2q | HELD | |
| ARTIVION INC | AORT | $1.1M | 48,481 | - | new | NEW | |
| BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | $995.4K | 130,628 | flat | 4q | HELD | |
| TELA BIO INC | TELA | $477.2K | 636,300 | +0.02pp | 7q | HELD | |
| ADAGIO MED HLDGS INC | ADGM | $455.5K | 698,989 | -0.14pp | 3q | -45.8%-$384.1K | |
| NEUROONE MED TECHNOLOGIES CO | NMTC | $251.6K | 82,767 | - | new | NEW | |
| ENVERIC BIOSCIENCES INC | ENVB | $248.4K | 180,000 | - | new | NEW | |
| MODULAR MED INC | MODD | $117.9K | 26,190 | flat | 2q | HELD | |
| QT IMAGING HLDGS INC | QTI | $62.0K | 15,236 | - | new | NEW | |
| ROCKET PHARMACEUTICALS INC | RCKTW | $1.5K | 400,000 | flat | 14q | HELD | |
| HUMACYTE INC | HUMAW | $477 | 49,998 | flat | 14q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $337.6M | 55.9% |
| Medical Devices | $103.4M | 17.1% |
| Wholesale & Distribution | $49.1M | 8.1% |
| Business Services | $38.5M | 6.4% |
| Software & IT Services | $19.0M | 3.1% |
| Healthcare Services | $17.3M | 2.9% |
| Insurance | $15.9M | 2.6% |
| Other sectors | $9.0M | 1.5% |
| Not classified | $14.5M | 2.4% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $604.3M | 59 | 17 | 10 | 21 | 34 | 48.6% | 45 |
| Q1 2026 | $697.3M | 76 | 23 | 24 | 15 | 15 | 45.1% | 44 |
| Q4 2025 | $635.7M | 68 | 27 | 8 | 16 | 10 | 53.7% | 48 |
| Q3 2025 | $395.2M | 51 | 15 | 6 | 12 | 16 | 59.5% | 44 |
| Q2 2025 | $261.8M | 52 | 10 | 31 | 6 | 12 | 58.8% | 44 |
| Q1 2025 | $335.8M | 54 | 14 | 15 | 6 | 11 | 64.3% | 45 |
| Q4 2024 | $355.4M | 51 | 22 | 9 | 5 | 10 | 60.0% | 45 |
| Q3 2024 | $252.2M | 39 | 9 | 3 | 12 | 18 | 67.9% | 45 |
| Q2 2024 | $369.5M | 48 | 14 | 10 | 8 | 16 | 68.6% | 45 |
| Q1 2024 | $335.8M | 50 | 21 | 4 | 11 | 14 | 58.9% | 45 |
| Q4 2023 | $439.2M | 43 | 9 | 9 | 7 | 18 | 76.2% | 44 |
| Q3 2023 | $323.1M | 52 | 17 | 10 | 12 | 11 | 57.7% | 45 |
| Q2 2023 | $393.2M | 46 | 17 | 12 | 5 | 15 | 69.3% | 45 |
| Q1 2023 | $202.3M | 44 | 18 | 10 | 10 | 19 | 75.0% | 42 |
| Q4 2022 | $270.4M | 45 | 14 | 5 | 5 | 18 | 74.7% | 44 |
| Q3 2022 | $314.7M | 49 | 7 | 6 | 7 | 19 | 69.9% | 45 |
| Q2 2022 | $266.2M | 61 | 17 | 13 | 6 | 21 | 54.8% | 46 |
| Q1 2022 | $302.3M | 65 | 15 | 10 | 16 | 19 | 59.4% | 46 |
| Q4 2021 | $331.7M | 69 | 22 | 12 | 9 | 14 | 52.2% | 45 |
| Q3 2021 | $313.7M | 61 | 13 | 20 | 16 | 25 | 50.0% | 46 |
| Q2 2021 | $402.3M | 73 | 16 | 19 | 22 | 32 | 43.6% | 47 |
| Q1 2021 | $492.7M | 89 | 22 | 19 | 33 | 22 | 38.1% | 44 |
| Q4 2020 | $488.5M | 89 | 25 | 11 | 44 | 25 | 36.4% | 47 |
| Q3 2020 | $505.0M | 89 | 33 | 24 | 16 | 21 | 36.7% | 47 |
| Q2 2020 | $342.7M | 77 | 30 | 15 | 27 | 22 | 36.9% | 45 |
| Q1 2020 | $298.4M | 69 | 36 | 13 | 15 | 34 | 49.8% | 45 |
| Q4 2019 | $419.8M | 67 | 32 | 14 | 16 | 25 | 50.9% | 45 |
| Q3 2019 | $310.5M | 60 | 23 | 9 | 22 | 31 | 43.6% | 45 |
| Q2 2019 | $414.8M | 68 | 24 | 21 | 16 | 24 | 45.6% | 45 |
| Q1 2019 | $370.4M | 68 | 22 | 26 | 12 | 21 | 38.6% | 45 |
| Q4 2018 | $274.5M | 67 | 0 | 0 | 0 | 0 | 37.6% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.